CoChat

NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes

Open access
Singh, Anju, Daemen, Anneleen, Nickles, Dorothee, Jeon, Sang-Min, Foreman, Oded, Sudini, Kuladeep, Gnad, Florian, Lajoie, Stephane, Gour, Naina, Mitzner, Wayne, Chatterjee, Samit, Choi, Eun-Ji, Ravishankar, Buvana, Rappaport, Amy, Patil, Namrata, McCleland, Mark, Johnson, Leisa, Acquaah-Mensah, George, Gabrielson, Edward, Biswal, Shyam, Hatzivassiliou, Georgia · 2021 · Clinical Cancer Research
Cited by 167

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Purpose: Stabilization of the transcription factor NRF2 through genomic alterations in KEAP1 and NFE2L2 occurs in a quarter of patients with lung adenocarcinoma and a third of patients with lung squamous cell carcinoma. In lung adenocarcinoma, KEAP1 loss often co-occurs with STK11 loss and KRAS-activating alterations. Despite its prevalence, the impact of NRF2 activation on tumor progression and patient outcomes is not fully defined. Experimental Design: We model NRF2 activation, STK11 loss, and KRAS activation in vivo using novel genetically engineered mouse models. Furthermore, we derive a NRF2 activation signature from human non–small cell lung tumors that we use to dissect how these genomic events impact outcomes and immune contexture of participants in the OAK and IMpower131 immunotherapy trials. Results: Our in vivo data reveal roles for NRF2 activation in (i) promoting rapid-onset, multifocal intrabronchiolar carcinomas, leading to lethal pulmonary dysfunction, and (ii) decreasing elevated redox stress in KRAS-mutant, STK11-null tumors. In patients with nonsquamous tumors, the NRF2 signature is negatively prognostic independently of STK11 loss. Patients with lung squamous cell carcinoma with low NRF2 signature survive longer when receiving anti–PD-L1 treatment. Conclusions: Our in vivo modeling establishes NRF2 activation as a critical oncogenic driver, cooperating with STK11 loss and KRAS activation to promote aggressive lung adenocarcinoma. In patients, oncogenic events alter the tumor immune contexture, possibly having an impact on treatment responses. Importantly, patients with NRF2-activated nonsquamous or squamous tumors have poor prognosis and show limited response to anti–PD-L1 treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-1985

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 167

Metadata

Authors
Singh, A., Daemen, A., Nickles, D., Jeon, S.-M., Foreman, O., Sudini, K., Gnad, F., Lajoie, S., Gour, N., Mitzner, W., Chatterjee, S., Choi, E.-J., Ravishankar, B., Rappaport, A., Patil, N., McCleland, M., Johnson, L., Acquaah-Mensah, G., Gabrielson, E., Biswal, S., & Hatzivassiliou, G.
Venue
Clinical Cancer Research
Published
2021-02-01
Volume
27
Issue
3
Pages
877-888
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3092968030
Cited by
167
References
19
FWCI
6.29
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-1985
The paper
Singh, A., Daemen, A., Nickles, D., Jeon, S.-M., Foreman, O., Sudini, K., Gnad, F., Lajoie, S., Gour, N., Mitzner, W., Chatterjee, S., Choi, E.-J., Ravishankar, B., Rappaport, A., Patil, N., McCleland, M., Johnson, L., Acquaah-Mensah, G., Gabrielson, E., . . . Hatzivassiliou, G. (2021). NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-1985

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.